ARVINAS, INC. (ARVN) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 200.00K USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 300.00K USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 567.90M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 675.10M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $200.00K | $300.00K | (m) | $567.90M | $675.10M | (m) |
| 2026-03-31 | (m) | (m) | $200.00K | $300.00K | (m) | $614.90M | $647.50M | (m) |
| 2025-12-31 | (m) | (m) | $200.00K | $400.00K | (m) | $685.40M | $717.90M | (m) |
| 2025-09-30 | (m) | (m) | $200.00K | $400.00K | (m) | $787.60M | $844.30M | (m) |
| 2025-06-30 | (m) | (m) | $200.00K | $500.00K | (m) | $861.20M | $909.30M | (m) |
| 2025-03-31 | (m) | (m) | $200.00K | $500.00K | (m) | $954.30M | $1.00B | (m) |
| 2024-12-31 | (m) | (m) | $200.00K | $600.00K | (m) | $1.04B | $1.09B | (m) |
| 2024-09-30 | (m) | (m) | $200.00K | $600.00K | (m) | $1.12B | $1.17B | (m) |
| 2024-06-30 | (m) | (m) | $200.00K | $700.00K | (m) | $1.23B | $1.28B | (m) |
| 2024-03-31 | (m) | (m) | $200.00K | $700.00K | (m) | $1.17B | $1.21B | (m) |
| 2023-12-31 | (m) | (m) | $200.00K | $800.00K | (m) | $1.26B | $1.30B | (m) |
| 2023-09-30 | (m) | (m) | $200.00K | $800.00K | (m) | $998.50M | $1.06B | (m) |
| 2023-06-30 | (m) | (m) | $100.00K | $900.00K | (m) | $1.04B | $1.08B | (m) |
| 2023-03-31 | (m) | (m) | $100.00K | $900.00K | (m) | $1.12B | $1.18B | (m) |
| 2022-12-31 | (m) | (m) | (m) | $1.00M | (m) | $1.21B | $1.27B | (m) |
| 2022-09-30 | (m) | (m) | (m) | $1.00M | (m) | $1.27B | $1.33B | (m) |
| 2022-06-30 | (m) | (m) | (m) | $1.00M | (m) | $1.34B | $1.41B | (m) |
| 2022-03-31 | (m) | (m) | (m) | $1.00M | (m) | $1.43B | $1.49B | (m) |
| 2021-12-31 | (m) | (m) | (m) | $1.00M | (m) | $1.50B | $1.58B | (m) |
| 2021-09-30 | (m) | (m) | (m) | $1.00M | (m) | $1.54B | $1.60B | (m) |
| 2021-06-30 | (m) | (m) | (m) | $1.00M | (m) | $600.58M | $644.03M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $2.00M | (m) | $651.27M | $681.77M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $2.00M | (m) | $688.53M | $717.37M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $2.00M | (m) | $248.56M | $271.95M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $2.00M | (m) | $242.70M | $262.58M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $2.00M | (m) | $262.83M | $282.45M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $2.00M | (m) | $280.87M | $301.64M | (m) |
| 2019-09-30 | (m) | (m) | (m) | $2.00M | (m) | $190.51M | $209.09M | (m) |
| 2019-06-30 | (m) | (m) | $71.50K | $2.00M | (m) | $159.17M | $172.05M | (m) |
| 2019-03-31 | (m) | (m) | $113.41K | $2.00M | (m) | $174.96M | $186.57M | (m) |
| 2018-12-31 | (m) | (m) | $154.46K | $2.00M | (m) | $187.83M | $199.28M | (m) |
| 2018-09-30 | (m) | (m) | $194.67K | $2.00M | (m) | $89.79M | $98.89M | (m) |
| 2017-12-31 | (m) | (m) | $159.26K | $151.12K | (m) | $39.17M | $66.85M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |